The leukocyte adherence inhibition assay as a measure of antitumor immunity in bladder cancer patients.

The leukocyte adherence inhibition test was used to assess antitumor immunity of patients with transitional cell carcinoma of the bladder. Patients and controls were tested against extracts of transitional cell carcinoma as well as extracts of renal cell carcinoma and normal bladder mucosa. Patients with transitional cell carcinoma had significantly greater reactivity compared to patients with other genitourinary disease or normal controls. With a pooled tumor extract from 6 different transitional cell tumors a positive response was obtained in up to 82 per cent of patients with other genitourinary disease. These results suggest that the leukocyte adherence inhibition test is a sensitive and fairly specific test of antitumor immunity in patients with transitional cell carcinoma of the bladder.